You are here

Able Laboratories Receives FDA Approval for Lithium Carbonate Capsules

SOUTH PLAINFIELD, N.J., June 29 /PRNewswire-FirstCall/ -- Able Laboratories, Inc. , today announced that it has received Food and Drug Administration approval for its Abbreviated New Drug Applications for Lithium Carbonate Capsules, USP 150mg, 300mg and 600mg, which are therapeutically equivalent to Lithium Carbonate Capsules, USP 150mg, 300mg and 600mg, of Roxane Laboratories, Inc. The incremental total sales for Able's newly approved 150mg and 600mg capsules (used in the treatment of manic episodes of bipolar disorder), is estimated to be approximately $2 million according to recent market data.

Able currently markets Lithium Carbonate Capsules, USP 300mg which represents the majority of the total sales in this product category. This approval represents the expansion of Able's line of Lithium-based products.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Further information on Able may be found on the Company's web site,

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs